1. Home
  2. CRSP vs PTEN Comparison

CRSP vs PTEN Comparison

Compare CRSP & PTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • PTEN
  • Stock Information
  • Founded
  • CRSP 2013
  • PTEN 1978
  • Country
  • CRSP Switzerland
  • PTEN United States
  • Employees
  • CRSP N/A
  • PTEN N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • PTEN Oil & Gas Production
  • Sector
  • CRSP Health Care
  • PTEN Energy
  • Exchange
  • CRSP Nasdaq
  • PTEN Nasdaq
  • Market Cap
  • CRSP 3.4B
  • PTEN 3.0B
  • IPO Year
  • CRSP 2016
  • PTEN 1993
  • Fundamental
  • Price
  • CRSP $40.53
  • PTEN $9.29
  • Analyst Decision
  • CRSP Buy
  • PTEN Buy
  • Analyst Count
  • CRSP 19
  • PTEN 13
  • Target Price
  • CRSP $77.13
  • PTEN $11.96
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • PTEN 9.5M
  • Earning Date
  • CRSP 02-19-2025
  • PTEN 02-05-2025
  • Dividend Yield
  • CRSP N/A
  • PTEN 3.44%
  • EPS Growth
  • CRSP N/A
  • PTEN N/A
  • EPS
  • CRSP N/A
  • PTEN N/A
  • Revenue
  • CRSP $202,829,000.00
  • PTEN $5,800,093,000.00
  • Revenue This Year
  • CRSP N/A
  • PTEN $34.14
  • Revenue Next Year
  • CRSP $724.16
  • PTEN N/A
  • P/E Ratio
  • CRSP N/A
  • PTEN N/A
  • Revenue Growth
  • CRSP 19.31
  • PTEN 73.11
  • 52 Week Low
  • CRSP $36.52
  • PTEN $7.15
  • 52 Week High
  • CRSP $91.10
  • PTEN $12.65
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.09
  • PTEN 69.70
  • Support Level
  • CRSP $36.52
  • PTEN $8.42
  • Resistance Level
  • CRSP $40.99
  • PTEN $8.81
  • Average True Range (ATR)
  • CRSP 1.78
  • PTEN 0.28
  • MACD
  • CRSP 0.23
  • PTEN 0.13
  • Stochastic Oscillator
  • CRSP 51.68
  • PTEN 84.03

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About PTEN Patterson-UTI Energy Inc.

Patterson-UTI Energy is one of the largest land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. It also provides directional drilling services and tool rental services in most US onshore oil and gas basins.

Share on Social Networks: